MK-677 (Ibutamoren) Month-by-Month: What to Expect in Your First 3 Months
At a glance
- Generic name / ibutamoren, also referred to by its development code MK-677
- Drug class / oral growth hormone secretagogue, ghrelin receptor (GHSR-1a) agonist
- Regulatory status / not FDA-approved for any human indication; sold in the US only as a research chemical (verify current status, checked 2025)
- Typical trial doses / 10 mg or 25 mg once daily, studied mainly in older adults or hip-fracture patients, not healthy young adults seeking physique change
- Early reported effects / increased appetite, deeper sleep, water retention, within the first one to two weeks
- Body composition signal / lean mass changes reported in trials over 8 to 24 months, with effect size dependent on age and activity level
- Key monitoring concern / effect on fasting glucose and insulin sensitivity
- Evidence gap / no controlled trial in healthy adults specifically studying a 12-week ibutamoren cycle for body composition purposes
What ibutamoren (MK-677) is, and what it is not
Ibutamoren, most often sold and discussed under its development code MK-677, is a small, orally active molecule that binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary. Activating that receptor triggers a pulse of endogenous growth hormone (GH) release, which in turn raises circulating insulin-like growth factor 1 (IGF-1). It is not a peptide itself, and it is not the same compound as injectable GH-releasing peptides such as GHRP-2, GHRP-6, or CJC-1295, though it is often discussed alongside them because it works on an overlapping axis.
Ibutamoren has never received FDA approval for any indication. It has been studied in placebo-controlled trials, mostly in older adults with age-related decline in GH output and in hip-fracture patients, not in healthy adults using it for muscle gain, fat loss, or sleep improvement. That distinction matters for how much weight the trial evidence can carry when applied to a different population.
The core, verifiable claim this page can support is narrow: MK-677 reliably raises IGF-1 in small placebo-controlled trials of older or medically frail adults, with detectable increases within one to two weeks and sustained elevation over the study period, while its effects on body composition, sleep, skin, and glucose metabolism in healthy young adults over a self-directed 12-week course have not been directly studied and are inferred by extrapolation. Readers should treat month-by-month "results" popular in online communities as self-report, not as trial-confirmed outcomes for that population.
Evidence boundary: what is established, what is plausible, what is not
Established from controlled trials (mostly in older or frail adults):
- MK-677 raises GH pulse frequency and IGF-1 concentration measurably within one to two weeks of daily oral dosing.
- Some trials report increased appetite and fluid retention as consistent early effects.
- Lean mass gains have been reported over multi-month to multi-year courses in older-adult and hip-fracture-recovery cohorts.
Plausible but not confirmed:
- Improvements in skin, hair, or nail appearance, which follow biologically from IGF-1's known role in tissue growth but have not been measured as trial endpoints in ibutamoren studies.
- Comparable lean-mass or fat-loss benefit in healthy, resistance-trained young adults, since most controlled data comes from older or catabolic populations.
- A specific month-by-month timeline (week 1 sleep changes, week 8 body composition, week 12 consolidation) that matches trial-reported changes in older adults transferred onto a different population's self-reports.
Not established:
- Long-term safety of continuous use in healthy adults over years.
- A verified target IGF-1 range or numeric glucose threshold that should guide dose adjustment outside a clinician's individualized assessment.
- Whether cycling on and off MK-677 changes outcomes or risk compared with continuous use; no controlled trial has tested this question directly.
What early trial data and self-reports describe, month by month
The following synthesizes what small trials have reported in their study populations alongside what is commonly described in user communities. Treat the trial-derived statements as the more reliable layer and the community-reported statements as anecdotal texture, not confirmation.
Weeks 1 to 4: appetite, sleep, and fluid shifts
Trials in older adults have reported increased GH pulsatility and IGF-1 elevation within the first one to two weeks of daily oral dosing. Increased appetite and mild fluid retention (sometimes described by users as a several-pound scale increase, largely water rather than fat or muscle) are commonly reported early effects, consistent with the known physiology of GH-driven sodium and water retention.
Self-reports also frequently describe deeper, more vivid sleep in the first two weeks. This is biologically plausible, since nocturnal GH pulsatility is tied to slow-wave sleep, but the specific effect size for MK-677 in healthy adults has not been independently confirmed here and would need verification against the primary trial literature before being stated as a measured outcome.
Weeks 5 to 8: where trial data and self-reports diverge
This is the period where the strongest divergence between evidence types appears. Trials in sedentary older adults have generally found lean mass increases without significant fat loss, underscoring that resistance training and diet, not the drug alone, drive fat-loss outcomes. Community reports from younger, physically active users often describe larger and faster body-composition changes, but these come from an untested population and are not directly comparable to the trial data.
Reported skin, hair, and nail changes in this window are common in self-report data but have not been trial endpoints for ibutamoren specifically. They should be read as plausible-but-unconfirmed, not as an established drug effect.
Water retention that develops early sometimes persists into this window for some users. Reducing dose or shifting dose timing are commonly discussed self-management strategies, not established clinical protocols, and any dose change should be made in consultation with a clinician who can also order fasting glucose and IGF-1 monitoring.
Weeks 9 to 12: consolidation, and what does not happen in three months
By week 12, users who combine consistent dosing with resistance training and adequate protein intake report the most noticeable cumulative changes, though this reflects self-report pattern rather than a controlled 12-week trial in that specific population.
What three months of MK-677 will not do is match the body-composition effect of pharmacological-dose exogenous GH therapy. The secretagogue mechanism amplifies the body's own GH output, which has a physiological ceiling that injectable GH does not share. Bone mineral density changes, where studied, required substantially longer intervention windows (a year or more) than a 12-week course, so readers should not expect measurable bone density change in this timeframe.
Dosing: what has been studied, not a personal recommendation
Clinical trials have used doses in the 10 mg and 25 mg per day range, generally taken once daily. Higher studied doses have been associated with greater IGF-1 elevation and more pronounced appetite and fluid-retention effects. This information describes what has been studied in trial populations; it is not a personalized dosing instruction. Anyone considering MK-677 should discuss dose, monitoring, and whether it is appropriate at all with a clinician, particularly given the lack of FDA oversight of the products sold as "MK-677" and the resulting uncertainty about purity and labeled dose accuracy.
Evening dosing is commonly discussed as preferable to align the GH pulse with the natural nocturnal GH surge, but no controlled comparison of morning versus evening dosing timing in this context is cited here with a verifiable source; treat this as a plausible, commonly repeated rationale rather than a confirmed trial finding.
No controlled trial has compared cycling (time on, then off) against continuous use in healthy adults. Multi-year continuous-use data in older adults has not shown clear evidence of pituitary desensitization, but this does not resolve the separate question of what happens with intermittent use in a younger population, which remains unstudied.
Side effects: documented versus anecdotal
More consistently documented across trials:
- Increased appetite
- Fluid retention (hands, feet, face), especially in the first several weeks
- Measurable, generally modest increases in fasting glucose in some participants, reflecting reduced insulin sensitivity
Reported anecdotally, less consistently documented in ibutamoren-specific trials:
- Tingling in the hands or feet, which if present should be evaluated clinically rather than assumed to be benign, since peripheral paresthesia can have several causes
- Prolactin elevation
Anyone with pre-diabetes, diabetes, or a strong family history of glucose intolerance should treat the glucose-related signal as a reason for closer monitoring and a lower threshold to involve a clinician before starting, not as a minor footnote.
Who is more or less likely to respond, based on trial populations
Most of the controlled evidence for lean mass and IGF-1 normalization comes from older adults with age-related decline in GH output, where ibutamoren moved IGF-1 toward younger-adult reference levels. Younger adults with already-normal GH pulsatility would be expected, on general endocrine principles, to see a smaller relative IGF-1 change, though this has not been directly quantified in a dedicated trial of that population.
GH and IGF-1 signaling supports muscle protein synthesis mainly in the presence of adequate protein intake and mechanical loading (resistance training). This is a general principle from GH-axis physiology and endocrine guidance, not a claim specific to a single ibutamoren trial, and it means that expectations should be tied to training and nutrition, not the drug alone.
People with pre-diabetes or impaired fasting glucose are a higher-risk group for worsening insulin resistance and should have that risk weighed explicitly, ideally with a clinician, before starting.
Reading an IGF-1 lab result
IGF-1 is the main biomarker trials use to track ibutamoren's pharmacologic effect. Reference ranges are age- and lab-specific and vary meaningfully between assay platforms, so this page does not provide a single universal target number to aim for. A rising IGF-1 that stays within your lab's age-adjusted reference range is a reasonable general goal; a level that your lab or clinician flags as elevated for your age warrants a conversation about dose, not self-directed continuation. Testing at baseline and again after several weeks of use, interpreted by a clinician against your specific lab's reference interval, is more useful than comparing against a number found online.
Evidence-review framework: reported experience versus controlled evidence
Use this framework to sort any specific claim about MK-677 you encounter, before deciding whether it should change your plan.
| Claim area | What controlled trials show | What is self-reported only | What can be concluded now | Next decision |
|---|---|---|---|---|
| IGF-1 rises within 1-2 weeks | Yes, in small placebo-controlled trials of older/frail adults | Consistent with community timelines | Established for the studied populations; extrapolation to healthy young adults is reasonable but unconfirmed | Baseline and follow-up IGF-1 testing, interpreted by a clinician |
| Increased appetite, early fluid retention | Yes, commonly reported trial effect | Widely and consistently reported | Established as a class effect | No action needed unless retention is severe or rapid; flag rapid swelling to a clinician |
| Deeper sleep / more vivid dreams | Biologically plausible via GH-sleep link | Frequently reported | Plausible, not independently confirmed for MK-677 in a verifiable trial cited here | Track your own sleep quality; do not assume a guaranteed effect |
| Lean mass gain over 8-12 weeks | Reported over months to years in older/frail cohorts | Frequently and often more dramatically reported in younger, trained users | Trial-confirmed only for older/frail populations; untested in healthy young adults directly | Judge your own results against training and diet, not trial numbers from a different population |
| Fat loss | Not shown without a caloric deficit in sedentary trial cohorts | Often attributed to the drug | Not established as a direct drug effect; likely mediated by training/diet | Do not rely on MK-677 alone for fat loss; a deficit is still required |
| Skin, hair, nail improvement | Not a trial endpoint in ibutamoren studies found here | Common anecdote | Plausible mechanism, unconfirmed outcome | Treat as a possible bonus, not a reason to start |
| Glucose / insulin sensitivity effect | Documented modest fasting glucose increase in some trial participants | Rarely tracked by users without testing | Established direction of effect; magnitude in a given individual is not predictable from trial averages | Get fasting glucose and HbA1c checked before and during use |
| Cycling vs. continuous use | Not directly compared in any controlled trial found here | Common community protocols (e.g., "12 weeks on, 4 off") exist without evidence base | Not established either way | Do not assume a cycling schedule is protective; ask a clinician if considering longer-term use |
| Long-term safety in healthy adults | Not established; longest cited data comes from older/frail cohorts | Not something self-reports can establish | Genuinely unknown | Reassess need for continued use periodically; this is not a settled question |
When to involve a clinician urgently
Seek prompt medical evaluation rather than continuing self-directed use if you notice new or worsening numbness or tingling in the hands (possible carpal tunnel-type symptoms), rapidly progressive swelling, signs of new-onset high blood sugar (excessive thirst, frequent urination, blurred vision), or any symptom that concerns you and does not resolve with stopping the product. These warrant clinical assessment, not adjustment of an unregulated compound on your own.
Common questions
Does MK-677 work the same way for everyone? No. The controlled evidence for IGF-1 and lean-mass response comes mostly from older adults with reduced baseline GH output. Younger adults with normal GH pulsatility, and people with impaired glucose regulation, are different populations whose responses and risks have not been directly studied in the same way.
Is MK-677 legal and FDA-approved? It is not FDA-approved for any human indication. It is generally sold as a research compound rather than a regulated drug. Regulatory status can change; verify current status directly with fda.gov before relying on this statement.
Will MK-677 cause fat loss by itself? Trial data in sedentary cohorts does not show significant fat loss from the drug alone; a caloric deficit is still required. Reports of fat loss from active users likely reflect the combined effect of training and diet alongside the drug, not the drug in isolation.
Does MK-677 suppress natural testosterone? No mechanism for testosterone suppression is described in the trial data reviewed for this page, since ibutamoren stimulates rather than replaces the GH axis. This statement should still be checked against the primary literature if it is decision-relevant for you, since it was not independently re-verified against a specific cited trial here.
What should I get tested before starting? A baseline fasting glucose, HbA1c, and IGF-1, interpreted by a clinician against your own lab's reference ranges, is a reasonable starting point given the documented glucose-related signal in trial data.
A note on the sources behind this page
During this revision, certain trial references and numerical data from the previous version could not be confirmed through direct review of original research sources. To avoid presenting unconfirmed figures as established facts, this update discusses MK-677 trial outcomes using broader language and indicates areas needing verification. Prior to reintroducing any specific trial citations with exact percentages, editors and reviewers must cross-check these claims against the underlying primary literature.
References
- U.S. Food and Drug Administration, drug approval and label database (general reference for GH-class regulatory status; MK-677/ibutamoren itself has no FDA-approved label, checked 2025): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019640
- American Diabetes Association, Standards of Care in Diabetes (general reference for glucose/insulin monitoring principles, not ibutamoren-specific): https://diabetesjournals.org/care/issue/47/Supplement_1
Specific ibutamoren trial citations from the prior version of this page require verification against the primary literature before being reinstated with precise figures. This flag should be resolved during medical and editorial review before publication.